{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-glp1-label-warning-removal-request:v1","objectPathId":"fda-glp1-label-warning-removal-request-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/","json":"https://peptidescanner.com/evidence/v1/objects/fda-glp1-label-warning-removal-request-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/fda-glp1-label-warning-removal-request-v1.md"},"story":{"slug":"fda-glp1-label-warning-removal-request","version":1,"domain":"Safety","dateInSource":"2026-01-13","sourceCheckedAt":"2026-07-29","publishedAt":"2026-07-29","peptideSlugs":["semaglutide","tirzepatide","liraglutide"],"peptides":[{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"},{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"},{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"}]},"claims":[{"id":"headline","text":"FDA requests removal of a warning from certain GLP-1 drug labels","sourceIds":["fda-glp1-label-warning-request-2026"]},{"id":"summary","text":"FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.","sourceIds":["fda-glp1-label-warning-request-2026"]},{"id":"paragraph-1","text":"FDA's communication says the agency requested that manufacturers remove suicidal behavior and ideation warning language from the labels of certain GLP-1 receptor agonist medicines.","sourceIds":["fda-glp1-label-warning-request-2026"]},{"id":"paragraph-2","text":"The FDA communication names Wegovy, Zepbound, and Saxenda. This update reports the agency's labeling request and does not provide an individualized interpretation of safety.","sourceIds":["fda-glp1-label-warning-request-2026"]}],"sources":[{"id":"fda-glp1-label-warning-request-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels","url":"https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"54078b9ff5fd214a22421477a8212968f12ef22637166a1626d937064e11cb5f"},"integrity":{"algorithm":"sha256","contentSha256":"260bafd16d6f0d422b8bc70d0a4a4a64bd45ca9d7f424a1ee57a5d3948a9cf00"}}